Apotex Inc.
http://www.apotex.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Apotex Inc.
A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen
Biogen has been granted new US patents for Tecfidera after generics already launched. It's unclear how Biogen will proceed but management could shed more light on the matter during the first quarter call.
Apotex Loses Moot Appeal On Canadian Zytiga Bar
Apotex fell again in its bid to prove that a key patent in Canada shielding Janssen’s Zytiga (abiraterone acetate) treatment for prostate cancer was obvious. However, the company had already succeeded in obtaining a marketing authorization in a separate action.
Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Nutraceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Apobiologix
- ApoPharma, Inc.
- Apotex Australia
- Arrow Pharmaceuticals Pty Ltd.
- Arrow Remedies Private Limited
- Arrotex Australia Group Pty Ltd
- Aveva Drug Delivery Systems, Inc.